---
title: "Tempus AI, Inc. (TEM.US) — 公司概況"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/TEM.US/overview.md"
symbol: "TEM.US"
name: "Tempus AI, Inc."
parent: "https://longbridge.com/zh-HK/quote/TEM.US.md"
datetime: "2026-04-05T06:36:56.873Z"
locales:
  - [en](https://longbridge.com/en/quote/TEM.US/overview.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/TEM.US/overview.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/TEM.US/overview.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/TEM.US/overview.md) | [简体中文](https://longbridge.com/zh-CN/quote/TEM.US/overview.md)


# Tempus AI, Inc. (TEM.US) — 公司概況

## 基本資訊

| 項目 | 詳情 |
|------|--------|
| 行業 | Life Sciences Tools and Services |
| 交易所 | US Market |
| 地址 | 600 West Chicago Avenue, Suite 510, Chicago, Illinois, United States |
| 官網 | [www.tempus.com](https://www.tempus.com) |

## 公司簡介

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses.

## 核心管理層

| 名稱 | 職位 |
|------|-------|
| Eric P. Lefkofsky | Co-Founder, CEO, President & Chairman |
| Ryan Fukushima | Chief Operating Officer |
| Andrew Polovin | Executive VP, General Counsel & Secretary |
| James Rogers | Chief Financial Officer |
| Ryan M. Bartolucci | Chief Accounting Officer |
| Peter J. Barris | Independent Director |
| Theodore J. Leonsis | Independent Director |
| Eric D. Belcher | Independent Director |
| Scott Gottlieb | Independent Director |

## 主要股東

| 名稱 | 佔比 | 報告日期 |
|------|-------|-------------|
| Eric P. Lefkofsky | 23.61% | 2026-03-26 |
| Bradley Alan Keywell | 7.19% | 2025-08-08 |
| The Vanguard Group, Inc. | 5.74% | 2025-12-31 |
| ARK Investment Management LLC | 5.28% | 2026-02-28 |
| Baillie Gifford & Co. | 4.89% | 2025-12-31 |
| Kimberly Keywell | 4.51% | 2025-09-30 |
| BlackRock, Inc. | 4.20% | 2025-12-31 |
| Catalytic Wealth RIA, LLC | 3.78% | 2025-12-31 |
| SoftBank Group Corp. | 3.02% | 2025-12-31 |
| Nikko Asset Management Co., Ltd. | 1.96% | 2025-12-31 |

## 業務構成

| 業務線 | 營收 | 佔比 |
|---------|---------|-------|
| Medical Labs & Research | 1271789000 | 100% |

```vega-lite
{
  "$schema": "https://vega.github.io/schema/vega-lite/v5.json",
  "title": "Tempus AI, Inc. Business Breakdown",
  "data": {
    "values": [
      {
        "segment": "Medical Labs & Research",
        "ratio": 100
      }
    ]
  },
  "mark": "arc",
  "encoding": {
    "theta": {
      "field": "ratio",
      "type": "quantitative"
    },
    "color": {
      "field": "segment",
      "type": "nominal"
    }
  }
}
```

## 地區分佈

| 地區 | 營收 | 佔比 |
|--------|---------|-------|
| United States | 1271789000 | 100% |


---

> **免責聲明: 本文僅供參考，不構成任何投資建議。**